 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...172173174175176177178179180181182...235236» |
- | Review, Journal: Chemotherapy for pancreatic cancer. (Pubmed Central) - Apr 18, 2019
As an alternative to radiation, other forms local therapies including radiofrequency ablation, irreversible electroporation, high-intensity focused ultrasound, microwave ablation and local anti-KRAS therapy (using siG12D-LODER) are currently under investigation...Selection of patient groups for specific therapy including cytotoxics is becoming a reality using assays based on drug cellular transport and metabolism, and molecular signatures. Going forward, high throughput screening of different chemotherapy agents using molecular signatures based on patients' derived organoids holds considerable promise.
- | Retrospective data, Journal: Toxicity of Chemotherapy Regimens in Advanced and Metastatic Pancreatic Cancer Therapy: A Network Meta-Analysis. (Pubmed Central) - Apr 17, 2019
Moreover, the incidence rates of nausea/vomiting and rash of Gemcitabine + S-1 regimen were higher compared with Gemcitabine regimen, while Gemcitabine + Cisplatin regimen had the highest incidence rate of nausea/vomiting. This study demonstrated that the hematologic toxicity of S-1 regimen was the lowest, while Gemcitabine regimen exhibited the lowest incidence rate of non-hematologic toxicity, providing guidance for the treatment of advanced/metastatic PC.
- ||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed: CheckMate 649: Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (clinicaltrials.gov) - Apr 17, 2019
P3, N=2005, Active, not recruiting, Sponsor: Bristol-Myers Squibb
This study demonstrated that the hematologic toxicity of S-1 regimen was the lowest, while Gemcitabine regimen exhibited the lowest incidence rate of non-hematologic toxicity, providing guidance for the treatment of advanced/metastatic PC. Recruiting --> Active, not recruiting
- | Enrollment change, Metastases: Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC (clinicaltrials.gov) - Apr 17, 2019
P2, N=150, Recruiting, Sponsor: Sun Yat-sen University
Recruiting --> Active, not recruiting N=70 --> 150
- | leucovorin calcium / generics
Journal, MSi-H Biomarker, IO Biomarker: Induction of CD3+ and FoxP3+ T Cells in Left-sided Colorectal Tumors After UFT/LV Chemotherapy. (Pubmed Central) - Apr 16, 2019
N=70 --> 150 The increase in TILs count, especially of CD3+ T cells and FoxP3+ regulatory T cells, after UFT/LV chemotherapy were specific to left-sided colorectal cancers.
- || AZD0156 / AstraZeneca
Enrollment closed, Combination therapy, Monotherapy, PARP Biomarker, Metastases: AToM: Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer (clinicaltrials.gov) - Apr 16, 2019
P1, N=84, Active, not recruiting, Sponsor: AstraZeneca
The increase in TILs count, especially of CD3+ T cells and FoxP3+ regulatory T cells, after UFT/LV chemotherapy were specific to left-sided colorectal cancers. Recruiting --> Active, not recruiting
- | Cyramza (ramucirumab) / Eli Lilly
Enrollment closed, Metastases: RAMIRIS: Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy (clinicaltrials.gov) - Apr 16, 2019
P2, N=111, Active, not recruiting, Sponsor: IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial initiation date: A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma (clinicaltrials.gov) - Apr 16, 2019
P1, N=24, Not yet recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Recruiting --> Active, not recruiting Initiation date: Nov 2018 --> Jul 2019
- |||||| Erbitux (cetuximab) / Eli Lilly
New trial, Metastases: ESTER: Folfirinox + Cetuximab Chemotherapy, in First Line, With Wild RAS and According to BRAF Status in Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 16, 2019
P, N=70, Completed, Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
- | Blincyto (blinatumomab) / Astellas, Amgen
New P3 trial: AALL1731: A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 16, 2019
P3, N=6720, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | leucovorin calcium / generics
Clinical, Journal: A Case of Metastasis of Ascending Colon Cancer to the Small Intestine That Was Diagnosed Based on Ileus (Pubmed Central) - Apr 13, 2019
...He received 5 courses of UFT/Leucovorin(LV)chemotherapy...Because the tumor appearance and pathological findings were similar to those of ascending colon cancer, the patient was diagnosed with metastasis of ascending colon cancer to the small intestine. We report our rare encounter with metastases of colorectal cancer to the small intestine.
- | leucovorin calcium / generics, tegafur/uracil / generics
Clinical, Journal: A Case of Spontaneous Esophageal Rupture That Required Operation during Adjuvant Chemotherapy for Transverse Colon Cancer (Pubmed Central) - Apr 13, 2019
We think that the spontaneous esophageal rupture occurred because of the frequent vomiting caused by the continued chemotherapy despite the severe side effects. Treatments must be selected by considering patients' life background and medical compliance, and common guidance in taking medications must be provided to elderly patients at the start of chemotherapy.
- | Avastin (bevacizumab) / Roche
Clinical, Journal: Three Long-Surviving Cases of Recurrent Rectal Carcinomas Treated Non-Surgically and Cured (Pubmed Central) - Apr 13, 2019
He attained CR quickly, and was cancer-free for 5 years. Collecting similar cases to analyze the key to successful treatment is important.
- || leucovorin calcium / generics
Does leucovorin add much at all? (Twitter) - Apr 13, 2019
- || Trial primary completion date: QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. (clinicaltrials.gov) - Apr 12, 2019
P1/2, N=79, Recruiting, Sponsor: NantKwest, Inc.
Collecting similar cases to analyze the key to successful treatment is important. Trial primary completion date: Jan 2019 --> Dec 2019
- | leucovorin calcium / generics, fluorouracil / generics, paclitaxel / generics
Journal: A Therapeutic Strategy for Chemotherapy-Resistant Gastric Cancer via Destabilization of Both β-Catenin and RAS. (Pubmed Central) - Apr 11, 2019
KYA1797K also efficiently suppressed tumors generated by re-engrafting the FOLFOX-resistant patient-derived xenograft (PDX) tumors, which also showed resistance to paclitaxel. Overall, the small-molecule approach degrading both β-catenin and RAS has potential as a therapeutic strategy for treating GC patients resistant to current standard chemotherapies.
- | Avastin (bevacizumab) / Roche
Clinical, P3 data, Journal, Head-to-Head: Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. (Pubmed Central) - Apr 11, 2019
P3
mXELIRI with or without bevacizumab is well tolerated and non-inferior to FOLFIRI with or without bevacizumab in terms of overall survival. mXELIRI could be an alternative to FOLFIRI as a standard second-line backbone treatment for metastatic colorectal cancer, at least for Asian patient populations.
- | Trial primary completion date, Metastases: SEQUENCE: Phase I/II Study of Nab-paclitaxel and Gemcitabine Followed by AG-mFOLFOX in Patients With Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) - Apr 11, 2019
P1/2, N=180, Recruiting, Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
mXELIRI could be an alternative to FOLFIRI as a standard second-line backbone treatment for metastatic colorectal cancer, at least for Asian patient populations. Trial primary completion date: Dec 2018 --> May 2019
- | leucovorin calcium / generics
Clinical, Journal: Neutrophilic eccrine hidradenitis in a patient with FOLFOX chemotherapy. (Pubmed Central) - Apr 11, 2019
A histological examination showed features of neutrophilic eccrine hidradenitis. To the best of our knowledge, this is the first reported case of neutrophilic eccrine hidradenitis due to FOLFOX.
- ||| Trial completion, Trial completion date, Metastases: POLAF: Phase II Trial to Assess FOLFIRI+Aflibercept Efficacy in Patients With Oxaliplatin-pretreated Metastatic Colorectal Cancer With or Without ACE Polymorphisms (clinicaltrials.gov) - Apr 11, 2019
P2, N=100, Completed, Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
To the best of our knowledge, this is the first reported case of neutrophilic eccrine hidradenitis due to FOLFOX. Active, not recruiting --> Completed | Trial completion date: May 2019 --> Dec 2018
- | Cyramza (ramucirumab) / Eli Lilly
Biomarker, Clinical, P3 data, Journal: Analysis of Angiogenesis Biomarkers for Ramucirumab Efficacy in Patients with Metastatic Colorectal Cancer from RAISE, a Global, Randomized, Double-Blind, Phase III Study. (Pubmed Central) - Apr 10, 2019
P3
Development of an assay appropriate for testing in clinical practice is currently ongoing. NCT01183780.
- | leucovorin calcium / generics, fluorouracil / generics, irinotecan / generics
Clinical, Journal: Influence of initial dose intensity on efficacy of FOLFIRINOX in patients with advanced pancreatic cancer. (Pubmed Central) - Apr 9, 2019
A high RDI for 5-FU bolus resulted in poor prognosis in terms of PFS (hazard ratio: 1.34; p = 0.022) and negatively correlated with objective response (coefficient: -0.70; p = 0.021), and a high RDI for CPT-11 positively correlated with objective response (coefficient: 1.02; p = 0.031). In conclusion, low and high RDIs for irinotecan and 5-FU bolus, respectively, resulted in poor FOLFIRINOX efficacy.
- | leucovorin calcium / generics
Journal: Genetic assessment and folate receptor autoantibodies in infantile-onset cerebral folate deficiency (CFD) syndrome. (Pubmed Central) - Apr 7, 2019
WES in one consanguineous family identified a PNKP gene abnormality that explained the polyneuropathy and also its contribution to the infantile CFD syndrome because the PNKP gene plays a dual role in both neurodevelopment and immune-regulatory function. Further research for candidate genes predisposing to FRα-autoimmunity is suggested to include X-chromosomal and non-coding DNA regions.
- | Clinical, Journal, Real-World Evidence: Improvement of Treatment Outcomes for Metastatic Pancreatic Cancer: A Real-world Data Analysis. (Pubmed Central) - Apr 7, 2019
Further research for candidate genes predisposing to FRα-autoimmunity is suggested to include X-chromosomal and non-coding DNA regions. Overall treatment outcomes for metastatic pancreatic cancer were significantly improved after introduction of FOLFIRINOX and gemcitabine plus nab-paclitaxel combination therapy in daily practice.
- | Avastin (bevacizumab) / Roche
Trial completion date, Trial primary completion date, Metastases: BeTRI: Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 7, 2019
P2, N=45, Active, not recruiting, Sponsor: Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Overall treatment outcomes for metastatic pancreatic cancer were significantly improved after introduction of FOLFIRINOX and gemcitabine plus nab-paclitaxel combination therapy in daily practice. Trial completion date: Sep 2018 --> May 2019 | Trial primary completion date: Sep 2018 --> May 2019
- | leucovorin calcium / generics
Retrospective data, Review, Journal: Folic acid/methylfolate for the treatment of psychopathology in schizophrenia: a systematic review and meta-analysis. (Pubmed Central) - Apr 5, 2019
Moreover, this treatment was well tolerated. However, because our results might exhibit a small-study effect, future studies with a larger sample should be conducted to obtain more robust results.
- | NN1213 / Novo Nordisk
Enrollment closed, Trial completion date, Trial primary completion date: NORMAL-R: Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum (clinicaltrials.gov) - Apr 5, 2019
P1, N=20, Active, not recruiting, Sponsor: Washington University School of Medicine
However, because our results might exhibit a small-study effect, future studies with a larger sample should be conducted to obtain more robust results. Recruiting --> Active, not recruiting | Trial completion date: Jul 2019 --> Mar 2020 | Trial primary completion date: Jul 2019 --> Mar 2020
- || Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Enrollment closed, Combination therapy: Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Apr 5, 2019
P2, N=60, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting | Trial completion date: Jul 2019 --> Mar 2020 | Trial primary completion date: Jul 2019 --> Mar 2020 Recruiting --> Active, not recruiting
- | Journal, IO Biomarker: Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges. (Pubmed Central) - Apr 5, 2019
Immunotherapy with either vaccines or immune checkpoint inhibitors has not produced any significant improvements in outcome of PDAC. Incorporating different approaches in therapy, including conventional, immunological, and others, is key in offering patients with the best possible care.
- | leucovorin calcium / generics
Clinical, Clinical Trial,Phase I, Clinical Trial,Phase II, Clinical Trial,Phase III, Journal: Nutraceuticals for major depressive disorder- more is not merrier: An 8-week double-blind, randomised, controlled trial. (Pubmed Central) - Apr 5, 2019
Incorporating different approaches in therapy, including conventional, immunological, and others, is key in offering patients with the best possible care. The adoption of a nutraceutical 'shotgun' approach to treating MDD was not supported, and appeared to be less effective than adding placebo to treatment as usual.
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
New trial: NOM-ERA: Non-Operative Management and Early Response Assessment in Rectal Cancer (clinicaltrials.gov) - Apr 3, 2019
P=N/A, N=68, Not yet recruiting, Sponsor: Washington University School of Medicine
- | Clinical, P3 data, Journal: Planned Safety Analysis of the ACTS-CC 02 Trial: A Randomized Phase III Trial of S-1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High-Risk Stage III Colon Cancer. (Pubmed Central) - Apr 3, 2019
The adoption of a nutraceutical 'shotgun' approach to treating MDD was not supported, and appeared to be less effective than adding placebo to treatment as usual. The completion rate of adjuvant SOX and its incidence of AEs were acceptable in patients with colon cancer.
- | leucovorin calcium / generics, fluorouracil / generics
Clinical, Journal: Survival Impact of CAPOX Versus FOLFOX in the Adjuvant Treatment of Stage III Colon Cancer. (Pubmed Central) - Apr 3, 2019
CAPOX may be associated with improved disease-free survival despite greater toxicities and lower RDI. Reducing adjuvant chemotherapy duration to 3 months would prevent 26% of patients from ever experiencing a DLT.
- ||||| pegilodecakin (LY3500518) / Eli Lilly
Trial initiation date, Combination therapy, Metastases: Sequoia: Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Apr 3, 2019
P3, N=566, Recruiting, Sponsor: Eli Lilly and Company
Reducing adjuvant chemotherapy duration to 3 months would prevent 26% of patients from ever experiencing a DLT. Initiation date: Nov 2016 --> Mar 2017
- ||||| Opdivo (nivolumab) / BMS
New P4 trial: CA209-8TT: Pan Tumor Rollover Study (clinicaltrials.gov) - Apr 2, 2019
P4, N=1200, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- | New P3 trial: DIRECT: A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer (clinicaltrials.gov) - Apr 2, 2019
P3, N=528, Not yet recruiting, Sponsor: Angiodynamics, Inc.
- | leucovorin calcium / generics, methotrexate / generics
Clinical, Journal: Evaluation of toxicity after acute accidental methotrexate ingestions in children under 6 years old: a 16-year multi-center review. (Pubmed Central) - Mar 30, 2019
The incidence of toxicity from pediatric single, acute ingestions of methotrexate is rare and when it occurs is generally limited to no or only minimally concerning effects. Because concentrations from single ingestions were consistent with low subtoxic exposures, we believe that home monitoring without hospital referral and without methotrexate specific therapy is reasonable in those with acute ingestions up to 20 mg.
- | Zaltrap (ziv-aflibercept IV) / Sanofi, Regeneron, Avastin (bevacizumab) / Roche
Clinical, Journal: Disease Control With FOLFIRI Plus Ziv-aflibercept (zFOLFIRI) Beyond FOLFIRI Plus Bevacizumab: Case Series in Metastatic Colorectal Cancer (mCRC). (Pubmed Central) - Mar 30, 2019
In these small real-world cohorts, clinical meaningful stable disease and overall survival on zFOLFIRI beyond progression on bevacizumab+FOLFIRI was observed in patients with mCRC. Further exploration of this approach is warranted.
- | Journal, IO Biomarker: Molecular effects of treatment of human colorectal cancer cells with natural and classical chemotherapeutic drugs: alterations in the expression of apoptosis-related BCL2 family members, including BCL2L12. (Pubmed Central) - Mar 29, 2019
The intrinsic apoptotic pathway is activated during treatment of CRC cells with common chemotherapeutic drugs. Moreover, BCL2L12 mRNA expression increases progressively during treatment, similarly to the expression of other BCL2 family genes favoring apoptosis and/or particular proapoptotic transcripts, thus suggesting a proapoptotic role for BCL2L12 in chemotherapy-treated CRC cells.
- | leucovorin calcium / generics, fluorouracil / generics
Journal: Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer. (Pubmed Central) - Mar 28, 2019
The FOLFOX-4 regimen would seem to obtain similar survival rates to those of standard therapy with topotecan in platinum-resistant ovarian cancer. Further randomized trials are warranted to confirm our findings.
- | Rituxan (rituximab) / Roche
Trial completion date, Trial primary completion date: LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma (clinicaltrials.gov) - Mar 28, 2019
P1, N=6, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Further randomized trials are warranted to confirm our findings. Trial completion date: Oct 2019 --> Oct 2020 | Trial primary completion date: Oct 2019 --> Oct 2020
- ||||| napabucasin (BBI608) / Sumitomo Pharma
Enrollment closed, Combination therapy, Metastases: CanStem303C trial: A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 27, 2019
P3, N=1253, Active, not recruiting, Sponsor: Boston Biomedical, Inc
Trial completion date: Oct 2019 --> Oct 2020 | Trial primary completion date: Oct 2019 --> Oct 2020 Recruiting --> Active, not recruiting
- ||| leucovorin calcium / generics
Recently had a pt on TAF/FTC/COBI/EVG & toxo Rx, +rebound (VL 500+;+M184I). Nonadherence most likely, but has anyone seen signif interxn b/n leucovorin (has 8 mg elemental Ca) and integrase inhibitor? https://t.co/dKIZtpjThi @CarlosdelRio7 @PaulSaxMD @mmPharmD @BradCutrellMD (Twitter) - Mar 26, 2019
- | leucovorin calcium / generics, tegafur/uracil / generics
Clinical, P2 data, Journal: A phase II randomized trial comparing neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in advanced squamous cell carcinoma of the pharynx or larynx. (Pubmed Central) - Mar 25, 2019
However, poorer compliance to CCRT and inferior LRC and PFS were observed in the ICT/CCRT arm. Optimizing the therapeutic ratio in both ICT and CCRT settings are necessary for developing a sequential strategy for patients with advanced-stage PLSCC.
- || TRK-950 / Toray
Enrollment open: A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 25, 2019
P1b, N=36, Recruiting, Sponsor: Toray Industries, Inc
Optimizing the therapeutic ratio in both ICT and CCRT settings are necessary for developing a sequential strategy for patients with advanced-stage PLSCC. Not yet recruiting --> Recruiting
- |||| Foxy-5 / WntResearch
New P2 trial: NeoFox: Foxy-5 as Neo-Adjuvant Therapy in Subjects With Wnt-5a Low Colon Cancer (clinicaltrials.gov) - Mar 21, 2019
P2, N=100, Recruiting, Sponsor: WntResearch AB
- || Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
New P1 trial, Metastases: Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy (clinicaltrials.gov) - Mar 21, 2019
P1, N=20, Not yet recruiting, Sponsor: Washington University School of Medicine
- | oxaliplatin / Generic mfg.
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date: 2 Versus 6 Hour Oxaliplatin Infusions in Patients with Gastrointestinal Cancers (clinicaltrials.gov) - Mar 20, 2019
P2, N=60, Recruiting, Sponsor: Emory University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: Jan 2024 --> Mar 2023 | Initiation date: Jan 2020 --> Mar 2019 | Trial primary completion date: Jan 2022 --> Mar 2021
- | Phase classification, Trial completion date, Trial termination, Trial primary completion date: Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study (clinicaltrials.gov) - Mar 19, 2019
P1, N=1, Terminated, Sponsor: University of Chicago
Not yet recruiting --> Recruiting | Trial completion date: Jan 2024 --> Mar 2023 | Initiation date: Jan 2020 --> Mar 2019 | Trial primary completion date: Jan 2022 --> Mar 2021 Phase classification: P=N/A --> P1 | Trial completion date: Aug 2019 --> Mar 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2019 --> Mar 2018; Closed early due to poor accrual.